drugset / Trial / NCT05530278
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
RandomizedParallel-groupOpen-labelTreatment
Summary
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The main objectives of this study are to assess the safety and pharmacokinetics of the combination therapy of galicaftor/navocaftor/ABBV-576.
Timeline
- Start
- 2022-09-20
- Primary completion
- 2022-11-29
- Completion
- 2022-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABBV-576 | Unknown | — | Oral |
| Subject | Galicaftor | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Navocaftor | Small molecule | — | Oral |
Indications
No indication recorded.